AGAH CONFERENCE 2026

Arbeitsgemeinschaft
für angewandte
Humanpharmakologie e.V.

Association for Applied
Human Pharmacology

»OPTIMISM, COURAGE, AND PRAGMATISM – HUMAN PHARMACOLOGY 2030«

25 and 26 February 2026, Frankfurt | Germany

24 February 2026 | Pre-Meeting-Workshop
»Physiology-Based Pharmacokinetic (PBPK) model application in Model-Informed Drug Development (MIDD)«

preliminary programme as of November 2025 - subject to change without notice

Venue:	Haus am Dom Domplatz 3 60311 Frankfurt am Main
Pre-Meeting Workshop	»Physiology-Based Pharmacokinetic (PBPK) model application in Model-Informed Drug Development (MIDD)«
Date:	Tuesday, 24 February 2026
Room:	Seminarraum
Workshop language:	English
AGAH Conference	»Optimism, Courage, and Pragmatism – Human Pharmacology 2030«
Date:	Wednesday, 25 February and Thursday, 26 February 2026
Room:	Großer Saal
Website:	www.agah.eu
Meeting language:	English

Fees:	Early registration Until 31 October 2025	Regular registration From 1 November 2025
Pre-Meeting Workshop (only)		
Member[1]	250.- Euro	300.- Euro
Regular/Guest	350.- Euro	400.- Euro
Junior scientist[2]	200.- Euro	--
Annual Conference (only)		
Member[1, 3, 4]	450.- Euro	600.- Euro
Regular[3]	650.- Euro	800.- Euro
Junior scientist[2, 3]	300.- Euro	--
Combi Ticket		
Member[1, 3, 4]	600.- Euro	750.- Euro
Regular[3]	800.- Euro	950.- Euro
Junior scientist[2, 3]	400.- Euro	--
Conference Get-together	included	included

[1]of AGAH e. V., ACRON, AHPPI, AFPT-Le Club Phase I, HEALIXIA, POLFEMED
[2]under age 30, reduced price only available at early-bird registration
[3]reduction of early registration fee by 100 €, if you submit a poster abstract and present a poster at the AGAH Conference
[4]reduction of early registration fee by 100 €, if you are retired (AGAH members only), no combination with other reductions

WELCOME

Dear colleagues

Emerging tools, like artificial intelligence and advanced model-informed drug development (MIDD), disrupt our industry. Early clinical development and clinical pharmacology in particular need to get ready for keeping pace and driving new paradigms in early medicines development. The AGAH Conference 2026 will focus on these cutting-edge game changers with sessions on:

- Model-Informed Drug Development – Progress and Outlook
- Dose Selection for Phase 2 and Phase 3 – Optimal and Optimus
- Overly Complex Early Phase Trials – Proposals for Improvement
- Artificial Intelligence Impacting Clinical Pharmacology – A Dynamic Field of Opportunities
- Regulatory Enablers of Innovative Early Medicines Development

We are looking forward to welcome you to the AGAH Conference 2026 in Frankfurt.

Joachim Höchel
President AGAH e. V.

Jörg Täubel
President Elect AGAH e. V.

Sybille Baumann
Past President AGAH e. V.

PROGRAMME COMMITTEE

Sybille Baumann
Rolf Burghaus
Klaus Francke
Joachim Höchel
Burkhard Kerlin
Ingrid Klingmann
Andreas Kovar
Gerd Mikus
Jörg Täubel
Robert Schultz-Heienbrok
Michael Zühlsdorf

TUESDAY, 24 FEBRUARY 2026

Pre-Meeting Workshop

»Physiology-Based Pharmacokinetic (PBPK) model application in Model-Informed Drug Development (MIDD)«

Chairs	Rolf Burghaus - Bayer AG Stephan Schaller - ESQlabs GmbH
13:00–13:15	Welcome and introduction into the workshop
13:15–14:00	PBPK - Whats that? Annika Schneider - Bayer AG
14:00–14:30	Break
14:30–15:00	PBPK and Special Populations Ibrahim Ince - Boehringer Ingelheim Pharma GmbH & Co. KG
15:00–15:30	Physiologically-Based Biopharmaceutics Modeling Erik Sjögren - Pharmetheus AB
15:30–16:00	PBPK and Drug-Drug Interactions Jan Schlender - Novartis Pharma GmbH
16:00–16:30	Break
16:30–17:30	Open Systems Pharmacology: Science Community and Qualified Software Suite Stephan Schaller - ESQlabs GmbH

18:00	Get-together (AGAH Member)
18:30	AGAH e. V. General Assembly/Mitgliederversammlung

DAY 1 · WEDNESDAY, 25 FEBRUARY 2026

09:00	Welcome and Introduction Joachim Höchel - Bayer AG
09:15–09:45	**Keynote Presentation** The Value Continuum of PKPD: From Post-Marketing to Preclinical Development Bernd Meibohm - University of Tennessee
09:45–10:00	Discussion
10:00–10:30	Networking and Poster Viewing during Break
Session 1 Chairs	**Model-Informed Drug Development – Progress and Outlook** Joachim Höchel - Bayer AG Andreas Kovar - Sanofi
10:30–11:00	Implementing the ICH M15 Model-Informed Drug Development Paradigm Jörg Lippert - Bayer AG
11:00–11:15	Discussion
11:15–11:30	Question-driven Practice of Disease Progression Modeling and other MIDD Approaches: Case-studies in Immunology and Oncology Sathej Gopalakrishnan - Merck KGaA
11:30–11:45	Applying MIDD in Practice: Extrapolating Upadacitinib Efficacy in Juvenile Idiopathic Arthritis Using PK, Exposure-Response Models, and Real-World Data Sven Mensing - AbbVie Deutschland GmbH & Co KG
11:45 - 12:00	From Efficient Lead Selection to Mechanistic Translation Henrik Cordes - Sanofi
12:00–12:30	Joint discussion of all presentations of Session 1
12:30–13:30	Networking and Poster Viewing during Lunch Break

DAY 1 · WEDNESDAY, 25 FEBRUARY 2026

Session 2	**Dose Selection for Phase II and Phase III - Optimal and Optimus**
Chairs	Gerd Mikus - Freie Universität Berlin Michael Zühlsdorf - Translational Science Consulting
13:30–14:00	Project Optimus and Dose Finding for Phase II and III in Oncology Sven Wind - Boehringer Ingelheim Pharma GmbH & Co. KG
14:00–14:30	Dose Finding for Small Molecules: Tyrosine Kinase Inhibitor Michael Zühlsdorf - Translational Science Consulting
14:30–15:00	Dose Finding for Monoclonals Bernd Meibohm - University of Tennessee
15:00–15:30	Discussion
15:30–16:00	Networking and Poster Viewing during Break

Session 3	**Overly Complicated Early Phase** Live on stage: Stakeholder Interviews about Challenges and Solutions
Chairs	Sybille Baumann - CRS Clinical Research Services Berlin GmbH Klaus Francke - Bayer AG
16:00–16:10	Introduction Klaus Francke - Bayer AG
16:10–16:25	Sponsor Perspective Fabian Müller - Boehringer Ingelheim Pharma GmbH & Co. KG
16:25–16:40	Investigator Perspective Jelle Klein - SGS Belgium NV
16:40–16:55	Regulatory Authority Perspective Claudia Riedel - Bundesinstitut für Arzneimittel und Medizinprodukte
16:55–17:10	Ethics Committee Perspective Gerd Mikus - Freie Universität Berlin
17:10–17:25	Participant Perspective
17:25–17:50	Audience Discussion with Panelists
17:50–18:00	Conclusion and Summary of the Discussion Sybille Baumann - CRS Clinical Research Services Berlin GmbH
18:00–20:30	Conference Get-together

DAY 2 · THURSDAY, 26 FEBRUARY 2026

AGAH Breakfast Session - Meet the Expert

Fruity snacks and valuable insights – breakfast conversations to foster mutual exchange with colleagues in their career development

Chairs	Sybille Baumann - CRS Clinical Research Services Berlin GmbH Klaus Francke - Bayer AG Ingrid Klingmann - Pharmaplex bv Gerd Mikus - Freie Universität Berlin
07:45–08:45	This very informal session is intended for young scientists who would like to get in contact with experts who have worked for several years in different areas of early clinical development, in CROs, in consulting, in industry, in regulatory, in academia… They are at your disposal for any questions on career pathways in early clinical development, crucial skills, training recommendations – and what else you always wanted to know. Breakfast will be served.

Session 4	**Speed Dating with Research by Young Scientists** Poster Pitches of selected abstracts
Chair	Joachim Höchel - Bayer AG
09:00–09:30	Based on the submitted abstracts (Deadline 17 November 2025) Three posters will be selected by the programme committee for 5-min oral presentations followed by 5 min for discussion.

DAY 2 · THURSDAY, 26 FEBRUARY 2026

Session 5	**Artificial Intelligence Impacting Clinical Pharmacology – A Dynamic Field of Opportunities**
Chairs	Burkhard Kerlin - Bayer AG Michael Zühlsdorf - Translational Science Consulting
09:30–11:30	Artificial intelligence is rapidly transforming clinical pharmacology — from optimizing drug dosing and predicting adverse drug reactions to accelerating trial design and supporting precision medicine. The benefits are compelling: optimized preparation and conduct if clinical trials, faster insights, tailored therapies, and improved patient safety. Yet, implementation must be thoughtful. Risks such as algorithmic bias, lack of transparency, data privacy concerns, and over-reliance on machine output remind us that AI should augment — not replace — clinical judgment and expertise. The challenge ahead is to integrate AI responsibly, ensuring that its adoption maximizes benefit without adding harm.
11:30–12:00	Networking and Poster Viewing during Break
Session 6	**Regulatory Enablers of Innovative Early Medicines Development**
Chairs	Ingrid Klingmann - Pharmaplex bv Robert Schultz-Heienbrok - Charité Research Organisation GmbH
12:00–12:30	Predictive Biomarkers in Drug Development -- Co-Developing Diagnostics-Medicines Tandems: Regulatory-Scientific Challenges and Current Initiatives Silvia Vogl - Paul-Ehrlich-Institut
12:30–12:40	Discussion
12:40–13:10	The Promise of GCP R3 Guideline: Risk Proportionality in Action – an Inspector's View Torsten Stemmler - Bundesinstitut für Arzneimittel und Medizinprodukte
13:10–13:20	Discussion
13:20–13:50	The Promise of the German Medical Research Act: A Specialised Ethics Committee for First-in-Human Studies – Faster, Higher, Stronger? Ulrike Artmeier-Brandt - Spezialisierte Ethik-Kommission für besondere Verfahren
13:50–14:00	Discussion
14:00–14:15	Concluding Remarks and Best Poster Prize Jörg Täubel - Richmond Pharmacology
14:15–15:00	Farewell Lunch Snack

SPEAKERS AND CHAIRS

Artmeier-Brandt, Ulrike, Dr • Spezialisierte Ethik-Kommission für besondere Verfahren • Bonn, Germany

Baumann, Sybille, Dr • CRS Clinical Research Services Berlin GmbH • Berlin, Germany

Burghaus, Rolf, Dr • Bayer AG • Wuppertal, Germany

Cordes, Henrik, Dr • Sanofi • Frankfurt am Main, Germany

Francke, Klaus, Dr • Bayer AG • Berlin, Germany

Gopalakrishnan, Sathej, Dr • Merck KGaA • Darmstadt, Germany

Höchel, Joachim, Dr • Bayer AG • Berlin, Germany

Ince, Ibrahim, Dr • Boehringer Ingelheim Pharma GmbH & Co. KG • Ingelheim am Rhein, Germany

Kerlin, Burkhard • Bayer AG • Wuppertal, Germany

Klein, Jelle, Dr • SGS Belgium NV • Antwerpen, Belgium

Klingmann, Ingrid, Dr • Pharmaplex bv • Wezembeek-Oppem, Belgium

Kovar, Andreas, Dr • Sanofi • Frankfurt am Main, Germany

Lippert, Jörg, Dr • Bayer AG • Leverkusen, Germany

Meibohm, Bernd, Prof. Dr • University of Tennessee • Memphis, United States

Mensing, Sven, Dr • AbbVie Deutschland GmbH & Co KG • Ludwigshafen am Rhein, Germany

Mikus, Gerd, Prof. Dr • Freie Universität Berlin • Berlin, Germany

Müller, Fabian, Dr • Boehringer Ingelheim Pharma GmbH & Co. KG • Biberach an der Riß, Germany

Riedel, Claudia, Dr • Bundesinstitut für Arzneimittel und Medizinprodukte • Bonn, Germany

Schaller, Stephan, Dr • ESQlabs GmbH • Saterland, Germany

Schlender, Jan, Dr • Novartis Pharma GmbH • Nürnberg, Germany

Schneider, Annika, Dr • Bayer AG • Leverkusen, Germany

Schultz-Heienbrok, Robert, Dr • Charité Research Organisation GmbH • Berlin, Germany

Sjögren, Erik, Prof. Dr • Pharmetheus AB • Uppsala, Sweden

Stemmler, Torsten, Dr • Bundesinstitut für Arzneimittel und Medizinprodukte • Köln, Germany

Täubel, Jörg, Dr • Richmond Pharmacology • London , United Kingdom

Vogl, Silvia, Dr • Paul-Ehrlich-Institut • Langen, Germany

Wind, Sven, Dr • Boehringer Ingelheim Pharma GmbH & Co. KG • Ingelheim am Rhein, Germany

Zühlsdorf, Michael, Dr • Translational Science Consulting • Bonn, Germany

EXHIBITION | SPONSORING

ARENSIA Exploration Medicine GmbH
GERMANY

Celerion Switzerland AG
SWITZERLAND

Dr. Falk Pharma GmbH
GERMANY

NUVISAN GmbH
GERMANY

Occams Coöperatie U.A.
THE NETHERLANDS

SGS Pharma
BELGIUM

WuXi AppTec
UNITED STATES OF AMERICA

Special thanks to the exhibitors for their support! Status November 2025

For further information, please click on the logo.

Artmeier-Brandt, Ulrike, Dr
Spezialisierte Ethik-Kommission für besondere Verfahren • Bonn, Germany

Dr Ulrike Artmeier-Brandt is a physician-scientist with dual board certification in Anaesthesiology (1998) and Clinical Pharmacology (2007). She holds a doctorate in medicine (Dr med., 1994) from Ludwig Maximilian University of Munich and participated in the postgraduate programme in public health at Heinrich Heine University Düsseldorf (2002–2004). Her academic and clinical career includes positions as a research fellow and assistant physician in anaesthesiology at the University Hospital of Würzburg and the University Hospital Witten-Herdecke. Her areas of clinical expertise include anaesthesiology, intensive care, and emergency medicine.
From 2001 to 2008, Dr Artmeier-Brandt served as project leader at Bayer HealthCare AG in the Department of Clinical Pharmacology. She was responsible for the design and conduct of early-phase clinical trials (Phase I), management of the in-house clinical unit, and implementation of quality and safety oversight processes. She was also a tutor for study nurse qualification programs within the AGAH e.V. Since 2008, she has worked as an independent scientific consultant and managing director of abc.GbR. Since 2010, she has been a scientific advisor to the Ethics Committee of the Bavarian Medical Association, where she evaluates clinical trials under the German Medicinal Products Act (AMG), EU Clinical Trials Regulation (CTR), Medical Device Regulation (MDR), and In Vitro Diagnostic Regulation (IVDR). She also advises on research projects under §15 of the German Medical Code of Conduct.
Since 23 June 2025, she is the chair of the new founded specialised ethics committee for special procedures.
Dr Artmeier-Brandt is an active member of the German Society for Pharmaceutical Medicine (DGPharMed) and the Association for Applied Human Pharmacology (AGAH).

Baumann, Sybille, Dr
CRS Clinical Research Group Berlin • Berlin, Germany

Dr. Sybille Baumann is medical doctor by profession and holds board certification as both anaesthesiology and clinical pharmacology.
Following approximately ten years of experience in anasthesiology, Sybille acqured experience in clinical trials,initially as an Investigator at the former IKP Bobenheim GmbH and later as the Deputy Medical Director at CRS Mannheim GmbH. In these roles, she conducted and oversaw phase I/IIa trials in both healthy subjects and patients, overseeing the entire process from planning until reporting. In January 2016, she assumed her current role as Medical Director at CRS Berlin GmbH, overseeing a unit with specific emphasis on First-in-Human Trials and clinical studies in women´s health and dermatology.

Burghaus, Rolf, Dr
Bayer AG • Wuppertal, Germany

Rolf Burghaus studied physics at the Heinrich-Heine-University Düsseldorf, receiving his diploma in 1995. He got his doctor degree in 1997 in the field of statistical physics, followed by a stay at the Virginia Tech as a visiting researcher.
Rolf Burghaus joined the central technology division of the Bayer AG in 2000 working on Data Mining and Artificial Neural Network technologies and applications.
After changing into Bayer's Pharma division, he led the modeling and simulation department in Clinical Pharmacology and now is head of Systems Pharmacology & Medicine in Pharmacometrics. Rolf Burghaus is a co-founder of Open-Systems-Pharmacology.

Cordes, Henrik, Dr
Sanofi • Frankfurt am Main, Germany

Francke, Klaus, Dr
Bayer AG • Berlin, Germany

Dr Klaus Francke is a medical doctor and board-certified Clinical Pharmacologist with over 20 years of experience in various roles within the medical field. His professional journey includes positions as a research physician and medical consultant with Contract Research Organizations such as CRS and Parexel. Additionally, Dr Francke has worked at the health authority GKV-SV/GBA, where he gained valuable insights into healthcare regulation and drug pricing. For the past eight years, Dr Francke has served as an Early Clinical Lead in the Research and Development department at Bayer, focusing on early clinical trials. His extensive experience equips him to provide valuable perspectives on career development and professional advancement in CROs, health technology assessment (HTA) authorities, and the pharmaceutical industry.

Gopalakrishnan, Sathej, Dr
Merck KGaA • Darmstadt, Germany

Dr Sathej Gopalakrishnan is currently employed at Merck Healthcare KGaA, Germany, as Senior Director and Global Head of Pharmacometrics and Systems Pharmacology. Previously, he has served as a Clinical Pharmacology Lead at Merck. Sathej is passionate about applying quantitative approaches spanning across Pharmacometrics, PBPK and QSP modeling to impact drug development. He received his PhD in Systems Biology with a thesis on mathematical modeling of viral dynamics under the Graduate Research Training Program PharMetrX at University of Potsdam, Germany.

Höchel, Joachim, Dr
Bayer AG • Berlin, Germany

Joachim Höchel is clinical pharmacologist at Bayer and has worked for more than 25 years in diverse areas of pharmacokinetics, most of these in preclinical and clinical development of new medicines. His focus areas include the efficient and comprehensive characterization of the pharmacokinetic and pharmacodynamic properties and the dose-exposure-response relationship of new medicines as well as drug-drug interactions. Joachim Höchel has authored and co-authored more than 75 peer-reviewed scientific articles and has been regularly invited to present at scientific conferences. Since 2023, Joachim Höchel has been member of the board and currently serves as President of AGAH.

Ince, Ibrahim, Dr
Boehringer Ingelheim Pharma GmbH & CO. KG • Ingelheim am Rhein, Germany

Kerlin, Burkhard
Bayer AG • Wuppertal, Germany

Burkhard Kerlin has a Master of Science in Clinical Research and has been contributing to the conduct of clinical studies in various positions for the last 30 years. After stations in ward management for sites in Phase 1 to 3, project management for a Phase 1 unit and study management on the sponsor side, he found his sweet spot in heading Bayer's Early Medical Writing department, where he was able to elaborate on the standardization and simplification of increasingly complex study designs, mainly in the early phase of the clinical development. Burkhard Kerlin is burning for successful cross-functional communication and collaboration, translating and moderating needs and demands between the various stakeholders of clinical studies. Being a member of and lecturer for the AGAH since the early 2000s, he has taken been elected AGAH regent in 2023.

Klein, Jelle, Dr
SGS Belgium NV • Antwerpen, Belgium

Dr Jelle Klein graduated as Medical Doctor in 2016 from the University of Antwerp with a Master of Science in Medicine and received board certification as specialist Pharmaceutical Medicine and Clinical Pharmacology in 2024. In October 2018, Dr Klein joined the SGS Phase I unit as Principal Investigator, gaining experience in the coordination and set-up of early phase clinical trials (in different areas as immunology, neurology, cardiology, etc.) while being responsible of the safety and wellbeing of the subjects on site as well as the analysis of the clinical data. Mid 2021, Dr Klein assumed the responsibility as Associate Medical Director at SGS CPU, supporting the CPU Medical Director in the creation of strategies supporting business innovations, specialization in therapeutic area of focus. Since mid 2022, he is CPU Medical Director, and overall responsible for medical and scientific aspects of the CPU early phase projects and interaction with other sites, Belgian authorities, and organizations like Healixia and

Klingmann, Ingrid, Dr
Pharmaplex bv • Wezembeek-Oppem, Belgium

Physician, specialized in General Medicine, Clinical Pharmacology and Pharmaceutical Medicine with over 30 years of experience in different senior medical, operational and managerial functions in pharmaceutical industry, CROs and clinical trial sites with focus on clinical trial design and management, ethical and regulatory aspects. Since January 2003 she has her own pharmaceutical development and site management support consulting company. Dr Klingmann is Chairman of the Board of the European Forum for Good Clinical Practice (EFGCP). Her broad professional background as physician with experience in patient care, clinical development, site management, regulatory affairs, clinical research ethics, and patient engagement enables Dr Klingmann to bridge the gaps between the interests and skills of all different stakeholders in medicines development with the aim to develop new patient-relevant treatments more efficiently. Having been a founding member of EUPATI, the European Patients Academy on Therapeutic Innovation, she has been and is working on numerous activities to enable and facilitate patient involvement in medicines development in practical terms through patient and sponsor education and guidance development. Since 2023 she is Co-Chair of EU-X-CT, the multi-stakeholder initiative to enable cross-border access to clinical trials for patients and investigators in Europe. Dr Klingmann is currently also Vice-President of PharmaTrain Federation, the not-for-profit organisation focussing on global standardisation and improvement of post-graduate training in medicines development sciences and President of EUFEMED, the European Federation of Exploratory Medicines. She also teaches on different clinical research and regulatory affairs topics in diploma and master courses at the University of Bonn, Germany, University of Basel, Switzerland, and the Université Libre de Bruxelles, Belgium.

Kovar, Andreas, Dr
Sanofi • Frankfurt, Germany

Lippert, Jörg, Dr
Bayer AG • Leverkusen, Germany

Meibohm, Bernd, Prof. Dr
University of Tennessee • Memphis, United States

Bernd Meibohm, PhD, FCP, FAAPS is a UTHSC Distinguished Professor of Pharmaceutical Sciences and Associate Dean for Research and Graduate Programs at the College of Pharmacy, The University of Tennessee Health Science Center, Memphis, Tennessee, USA. He also serves as Chair of the University of Tennessee Department of Pharmaceutical Sciences and holds the Harriet S. Van Fleet Endowed Professorship in Pharmaceutics.

Dr Meibohm received his pharmacy degree and doctorate in pharmaceutics from Technical University Carolo-Wilhelmina, Braunschweig, Germany. After completion of a clinical pharmacology research fellowship at the University of Florida in 1997, he joined the faculty of the University of South Carolina, and in 1999 the University of Tennessee.

Dr Meibohm's scientific interests include bacterial and viral infectious diseases, pediatric pharmacotherapy and the application of pharmacometric modeling and simulation techniques in preclinical and clinical drug development, with specific focus on therapeutic proteins. His research has resulted in over 230 scientific papers and book chapters (>14,000 citations; h-index 58), three textbooks, 200 abstracts, and over 250 invited scientific presentations to national and international audiences.

Dr Meibohm is a Fellow of the American Association of Pharmaceutical Scientists (AAPS) and the American College of Clinical Pharmacology (ACCP). He was the President of ACCP 2014-2016 and served on its Board of Regents 2008-2018. He also served as 2010 Chair for the 'Pharmacokinetics, Pharmacodynamics and Drug Metabolism' section of AAPS, as 2016-2019 Member-at-Large on the Board of Directors of AAPS, and has recently completed his term as member of the Board of Trustees of the International Society of Pharmacometrics (ISoP). Dr. Meibohm is also serving as a member of the editorial advisory boards of seven peer-reviewed scientific journals, including the Journal of Clinical Pharmacology, Clinical Pharmacokinetics, and The AAPS Journal.

Mensing, Sven, Dr
AbbVie Deutschland GmbH & Co KG • Ludwigshafen am Rhein, Germany

Sven leads a group of 40 modeling and data experts supporting the most challenging modeling & simulation activities in Clinical Pharmacology at AbbVie. Using mechanistic mathematical models and advanced statistical tools, his pharmacometrics team delivers data driven assessments to optimize AbbVie's clinical development strategies for speed, size, and insight. Sven joined Abbott/AbbVie in 2008 where he contributed to the success of numerous assets (including Humira, Mavyret, Venetoclax and many more) striving towards replacing the need to observe with the ability to predict by using science, math, and IT.
Sven holds a PhD in Medical Informatics from the University of Heidelberg and a master's degree in Biomathematics from the University of Greifswald. Sven was named Senior Research Fellow in 2023.

Mikus, Gerd, Prof. Dr
Freie Universität Berlin • Berlin, Germany

Müller, Fabian, Dr
Boehringer Ingelheim Pharma GmbH & Co. KG • Biberach an der Riß, Germany

PD Dr Fabian Müller is a board-certified Clinical Pharmacologist with extensive experience in early drug development. He currently leads a team conducting Phase I trials in healthy volunteers at Boehringer Ingelheim. His previous roles include strategic leadership for early clinical trials in therapeutic area Mental Health and interim head of the Human Pharmacology Center, Boehringer Ingelheim's phase I unit. He is a university lecturer at Erlangen University and an expert in transporter-mediated drug-drug interactions. PD Dr Müller is passionate about people development, learning, and innovation in early drug development.

Riedel, Claudia, Dr
Bundesinstitut für Arzneimittel und Medizinprodukte • Bonn, Germany

Ärztin, klinische Pharmakologin

Seit 2001 im BfArM

2009 Fachgebietsleitung der Geschäftsstelle Kommission off-label und der KAKJ

Seit 2016 Fachgebietsleitung klinische Prüfung

Seit 2020 Fachgruppenleitung klinische Prüfung

Schaller, Stephan, Dr
ESQlabs GmbH • Satterland, Germany

Schlender, Jan, Dr
Novartis Pharma GmbH • Nürnberg, Germany

Schneider, Annika, Dr
Bayer AG • Leverkusen, Germany

Dr Annika Schneider is PBPK Leader within the Model-Informed Drug Development department at Bayer AG. She earned her PhD for her work on „Model-informed Treatment Optimization of Liver Cirrhosis Patients“ from RWTH Aachen University in collaboration with Bayer AG. Since 2021, Annika has been working in model-informed drug development, specializing in Physiologically Based Pharmacokinetic (PBPK) modeling. In 2024, she has taken on the role of PBPK Leader.

Schultz-Heienbrok, Robert, Dr
Charité Research Organisation GmbH • Berlin, Germany

Sjörgen, Erik, Prof. Dr
Pharmetheus AB • Uppsala, Sweden

Dr Erik Sjögren serves as a principal consultant and the Scientific Lead for the PBPK/PBBM-Platform at Pharmetheus. His research is centered on mechanistic and physiologically based modeling and simulation to support drug development in all phases, adopting techniques such as physiologically based pharmacokinetic (PBPK), physiologically based biopharmaceutics modeling (PBBM), and quantitative system pharmacology (QSP). In addition to his role at Pharmetheus, he serves as an Associate Professor in Biopharmaceutics at the Department of Pharmaceutical Biosciences at Uppsala University.

Stemmler, Torsten, Dr
Bundesinstitut für Arzneimittel und Medizinprodukte • Köln, Germany

Täubel, Jörg, Dr
Richmond Pharmacology • President-elect AGAH • London, United Kingdom

Dr Jorg Taubel is medical practitioner and CEO of Richmond Pharmacology, a centre of excellence for experimental medicine studies, which he co-founded in 2001. A specialist in clinical pharmacology, Dr Taubel has extensive experience in cardiology, neurology, gastroenterology, and ethnic bridging studies. He was Principal Investigator in over 500 clinical trials in Phases 1 – 3. He is an MHRA recognised investigator for First in Human trials involving healthy and/or patient participants. Most recently Dr Taubel has dosed the first patient in the pioneering global FIH study of NTLA-2001, the first CRISPR-Cas9 in vivo gene editing for transthyretin (TTR) amyloidosis. Working in close collaboration with Professor Julian Gillmore at Royal Free Hospital, Dr Taubel has enrolled the largest cohort of ATTR heart failure patients in five clinical studies. Dr Taubel also established the Richmond Research Institute, a not-for-profit organisation dedicated to academic research to improve and save lives.

Vogl, Silvia, Dr
Paul-Ehrlich-Institut • Langen, Germany

Wind,Sven, Dr
Boehringer Ingelheim Pharma GmbH & Co. KG • Ingelheim am Rhein, Germany

Position: Clinical Pharmacology Lead, Team lead Oncology; Clinical Pharmacology and Safety Science at Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany
• Study and Project Pharmacokineticist for various oncology and non-oncology projects at Dept of DMPK, Boehringer Ingelheim Pharma GmbH & Co. KG], [2007-2013]
• Clinical Pharmacology Project Lead for oncology, respiratory and CNS projects at Dept of Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG], [2013-2024]
• Teamlead of Clinical Pharmacology Oncology Team 2 at Clinical Pharmacology and Safety Science, Boehringer Ingelheim Pharma GmbH & Co. KG [since 2024]

Zühlsdorf, Michael, Dr
Translational Science Consulting • Bonn, Germany

Michael is a Senior Translational Research Advisor for Oncology at Merck KGaA and consultant for Translational Medicine. Michael has more than 30 years of working experience in the pharmaceutical industry covering both, research, and drug development. His main experiences and interests are in the fields of translational research, biomarker development, stratified medicine, clinical pharmacology and the co-development of drug and diagnostics.
Formerly Michael had the positions as Global Head Translational and Biomarker Research Oncology, Global Head Clinical Pharmacology Oncology Division and PK/PD Markers at Merck. Before joining Merck he was holding positions as a Global Head of Integrative Expression Profiling at Novartis, Basel and Head of Biomarker and Pharmacogenetics at Bayer, Wuppertal.
Michael studied pharmacy at the Regina Pacis University Bonn and Chemistry at University Cologne, Germany and received its Ph.D. from the Regina Pacis University Bonn, Germany. He is the author or co-author of more than 50 scientific publications.